Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + vicriviroc
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + vicriviroc is a combination therapy evaluated for the treatment of advanced or metastatic microsatellite stable (MSS) or mismatch repair proficient (pMMR) colorectal cancer. Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Vicriviroc is a small-molecule antagonist of the C-C motif chemokine receptor 5 (CCR5), which blocks signaling involved in tumor progression and immune cell trafficking. The combination was studied in phase 2 clinical trials but demonstrated limited antitumor activity in this patient population; toxicity was manageable[1][2][3][7].
- Brand names
- Keytruda
- Other names
- pembrolizumab + vicriviroc
02
Targets
CCR5 (C-C chemokine receptor type 5)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + vicriviroc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + vicriviroc.